Bioethics News

Two Former Pharma Execs First to Be Charged in Generic Price-Fixing Probe

December 14, 2016

(STAT News) – Two former Heritage Pharmaceuticals executives were accused by federal authorities on Wednesday of conspiring with rivals to fix prices for a widely used antibiotic, the first criminal charges to stem from a two-year investigation into price collusion among generic drug makers. Jeffrey Glazer, who was the chief executive officer, and Jason Malek, the former president, allegedly worked with other generic drug makers to fix the market for doxycycline hyclate, an antibiotic, and a diabetes treatment called glyburide, according to documents filed in federal court in Philadelphia.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.